STELLARIS: A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis

Brief description of study

This study is being conducted to identify whether the study drug (cenicriviroc or CVC) is safe and effective for the treatment of people with nonalcoholic steatohepatitis (NASH). CVC is an investigational medicine. This means that CVC is still being studied. It also means that the Food and Drug Administration (FDA) or other Regulatory Authorities have not approved CVC for the treatment of liver fibrosis in patients who have NASH. Steatohepatitis is a type of liver disease known as fatty liver where the cells in the liver have abnormal accumulation of fat. One common form of fatty liver disease is caused by drinking too much alcohol. However, another form of fatty liver not caused by increased alcohol consumption is called nonalcoholic fatty liver. Liver fibrosis is a condition developed as a consequence of inflammation and buildup of scar tissue in the liver.

Clinical Study Identifier: s16-01976 Identifier: NCT03028740
Principal Investigator: James S Park.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.